Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features by unknown
ORIGINAL PAPER
Family history of hematologic malignancies and risk of multiple
myeloma: differences by race and clinical features
MaryAnn E. VanValkenburg1 • Gwendolyn I. Pruitt2 • Ilene K. Brill2 •
Luciano Costa3,4 • Maryam Ehtsham2,5 • Ian T. Justement2,5 • Racquel D. Innis-Shelton3,4 •
Donna Salzman3,4 • E. Shyam P. Reddy6 • Kelly N. Godby3,4 • Fady M. Mikhail7 •
Andrew J. Carroll7 • Vishnu B. Reddy1,4 • Ralph D. Sanderson1,4 • Louis B. Justement4,8 •
Paul W. Sanders4,9,10 • Elizabeth E. Brown1,4,11
Received: 8 June 2015 / Accepted: 16 October 2015 / Published online: 23 November 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Purpose Multiple myeloma (MM) is the most common
hematologic malignancy affecting Blacks in the USA, with
standardized incidence rates that are twofold to threefold
higher than Whites. The rationale for the disparity is
unclear.
Methods Using participants enrolled in the Molecular
And Genetic Epidemiology study of myeloma (259 MM
cases; 461 controls), we examined the risk of MM asso-
ciated with family history of cancer, differences by race
and among cases, defining clinical features. Risk estimates
were calculated using odds ratios and corresponding 95%
confidence intervals from logistic regression adjusted for
confounders.
Results Overall, MM risk in cases with relatives affected
with any hematologic malignancy was significantly ele-
vated compared to controls (OR 1.89, 95% CI 1.25–2.86).
Myeloma risk associated with a family history of MM was
higher than the risk associated with any hematologic
malignancy (OR 3.75, 95% CI 1.75–8.05), and the effect
was greater for Blacks (OR 20.9, 95% CI 2.59–168) than
Whites (OR 2.04, 95% 0.83–5.04), among cases with early
onset (B60 years; OR 4.58, 95% CI 1.21–17.3) and with
increasing numbers of affected relatives (p trend = 0.001).
Overall, frequencies of end organ damage differed in cases
with relatives affected with any hematologic malignancy
and significantly more cases exhibited j light chain
restriction (OR 3.23, 95% CI 1.13–9.26).
Conclusions The excess risk of MM observed in Blacks
and the variation in clinical features observed in MM
patients according to family history of hematologic
malignancy may be attributed to a shared germline and
environmental susceptibility.
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Introduction
Multiple myeloma is a plasma cell malignancy charac-
terized, in part, by prolonged survival and accumulation
of clonal plasma cells in the bone marrow microenvi-
ronment, presence of monoclonal protein in serum, urine
or both, and end organ damage [1]. Standardized inci-
dence rates of MM are increasing, advancing it to the
second most common hematologic malignancy and
accounting for 1 % of all cancers in the USA [2].
Although the etiology of MM is unclear, it is preceded by
an asymptomatic plasma cell dyscrasia known as Mono-
clonal Gammopathy of Undetermined Significance
(MGUS) [3, 4] that carries a risk of progression to frank
MM of 1 % per year [5]. Other confirmed risk factors for
MM include increasing age, male sex, Black race and a
family history of cancer [6].
Multiple myeloma is the most common hematologic
malignancy affecting Blacks in the USA, with standard-
ized incidence rates that are twofold to threefold higher
than Whites [7, 8], and with an earlier age of onset [9].
Rationale for the observed disparity is unclear. However,
evidence suggests a shared genetic predisposition.
Several lines of evidence support an inherited germline
susceptibility. Familial clustering of MM in several case
series [10–13], in addition to family aggregation [14, 15],
epidemiologic case–control [16, 17], and registry-based
[18, 19] studies have consistently shown excess MM risk
among first-degree relatives of patients with MM. In
addition, in the only study published to date that included
both Blacks and Whites, Brown et al. [20] showed that
MM risk was significantly increased in Black MM
patients with an affected first-degree relative, providing a
possible rationale for the difference in incidence observed
by race.
Familial aggregation of MM and the epidemiologic
differences observed by race suggest a complex etiology,
which may be influenced by shared genetic factors,
environmental exposures, behaviors and underlying dif-
ferences in tumor biology. We conducted a comprehen-
sive investigation to expand upon the existing report to
evaluate differences in the contribution of hematologic
malignancies and solid tumors among relatives of Black
and White patients with MM. To our knowledge this is
the first study to include evaluations of MM-defining
clinical features with family history of cancer, which may
provide important insight into underlying differences in
the clinical presentation of MM by race.
Materials and methods
Study population
We included participants enrolled in the Molecular And
Genetic Epidemiology (iMAGE) study of myeloma to
characterize the contribution of family history of cancer on
the risk of MM, differences by race and among cases only,
the presence of defining clinical features. The iMAGE
study was designed to evaluate the effects of biological,
chemical, physical, social and genetic influences on the risk
of MM and direct comparisons by self-reported Black and
White race. Approvals from the appropriate Institutional
Review Boards in accordance with the Declaration of
Helsinki were obtained prior to study initiation, and
informed consent was obtained from all individual partic-
ipants included in the study.
Case definition
Eligible cases were recruited from the University of Ala-
bama at Birmingham Hematology and Medical Oncology
clinics (Birmingham, Alabama) and the Morehouse School
of Medicine (Atlanta, Georgia). Patients with a diagnosis
of MM were identified based on the ICD-9 classifications
(203) or International Classification of Diseases for
Oncology third revision code 9732/3 and confirmed based
on the revised and updated International Multiple Myeloma
Working Group classification criteria for MM. Criteria
include the cumulative presence of clonal bone marrow
plasma cells C10 % or biopsy proven bony or extra-
medullary plasmacytoma and presence of one or more
MM-defining events including organ damage (hypercal-
cemia, renal insufficiency, anemia, or lytic bone lesions or
severe osteopenia or pathologic fractures attributed to a
plasma cell proliferative disorder), or in the absence of end
organ damage, clonal bone marrow plasma cells C60 %,
serum free light chain (FLC) ratio C100, or more than one
focal bone lesion ([5 mm) identified using magnetic res-
onance imaging (MRI) [21]. Each MM case was reviewed
by an expert panel to ensure consistent case definitions and
to minimize phenotype misclassification.
Clinical features
Diagnostic and defining clinical features including clonal
bone marrow plasma cells (%), serum monoclonal (M)-
protein (median, range), abnormal FLC ratio (\0.26 or
[1.65), immunoglobulin (Ig) isotype (IgA, IgG, IgM, IgD,
biclonal), clonality (kappa, lambda, biclonal), b2-mi-
croglobulin (median, range), albumin (median, range), end
organ damage [presence of hypercalcemia (serum calcium,
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[11.5 mg/dL), renal insufficiency (serum creatinine,
[177.0 lmol/L ([2 mg/dL) or estimated creatinine
clearance \40 mL/min per 1.73 m2), anemia (nor-
mochromic, normocytic with hemoglobin[2 g/dL below
the lower limit of normal or hemoglobin\10 g/dL), bone
lesions (radiologic evidence of lytic lesions, severe
osteopenia or pathologic fractures)] [21], and the revised
and updated International Staging System (ISS) [22] were
determined by laboratory studies, medical history, and
physical examination, respectively.
Control selection
Controls were sampled from an existing and updated
population-based database established and maintained by
the Survey Research Unit (University of Alabama at
Birmingham). This database includes US Census and
Centers for Disease Control population databases estab-
lished from list-assisted random digit dialing methods and
used previously for this, and other large-scale population-
based epidemiology studies [23, 24]. Eligible controls were
residents of Alabama and Georgia, 21 years of age or older
without a self-reported history of MGUS, smoldering
myeloma (SMM), MM, or other cancer excluding non-
melanoma cancers of the skin. One to two controls were
randomly selected and frequency matched to cases on age
(±5 years), sex, race (Black, White), and geography.
Definition of family history of cancer
Detailed information, including family history of cancer,
sociodemographic features, smoking and alcohol use,
medication use, as well as residential, lifetime occupa-
tional, medical, surgical, and reproductive histories, was
obtained using a structured questionnaire administered by
trained interviewers at the time of enrollment. We defined
family history of cancer as a self-report of one or more
first-degree (parent, sibling, child), second-degree (grand-
parent, aunt, uncle, niece, nephew), or third-degree (first-
cousin) relatives with any hematologic malignancy
including MM, non-Hodgkin lymphoma [NHL; which
included lymphoma not otherwise specified (NOS)],
Hodgkin lymphoma (HL), leukemia, or any solid tumor
(non-hematologic malignancy). Family history of any
hematologic malignancy was defined using ICD-9 classi-
fication including MM (203), NHL (202), HL (201), or
leukemia (204–208). As a sensitivity assessment, MM was
defined with and without self-reported affected relatives
with bone cancer NOS and later excluded from the MM
definition to minimize misclassification. We categorized
affected relatives as first-degree and jointly as any relative.
Family size was not collected.
Statistical analysis
We evaluated family history of cancer with MM risk
overall and stratified by race, early age of onset
(B60 years, defined by median) and sex of the MM case as
well as the affected relative to evaluate sex-linked germline
susceptibility. Among cases only, we evaluated family
history of cancer with the presence of defining clinical
features. We estimated the risk of MM (case–control
analysis) and risk of family history of cancer in MM
patients (case-only analysis) using the odds ratio (OR) and
corresponding 95% confidence interval (CI) calculated
from logistic regression adjusted for confounders including
sex, age (continuous), level of education (Bhigh school
graduate vs. some college, college graduate, or post-grad-
uate education) and race (White, Black) in analyses not
stratified by these variables. Other potential confounders
were evaluated, including smoking status, alcohol con-
sumption, and annual household income at the time of
enrollment, but were excluded from final models because
they were not substantially related to MM or family history
of cancer. Tests for statistical significance of trend were
conducted using multivariable logistic regression with an
incremental increase in the number of affected relatives per
category modeled as a continuous variable. The strength of
linearity between clinical laboratory variables and a family
history of any hematologic malignancy among MM cases
was examined using regression coefficients and standard
errors generated by linear regression adjusted for con-
founders. Statistical significance, based on multivariable
logistic models, was calculated using the maximum like-
lihood v2 test, and differences between strata were deter-
mined using the Mantel–Haenszel v2 test for homogeneity.
Individuals with missing data for family history of cancer
variables or clinical features were excluded from analyses.
A two-sided p value B0.05 was considered statistically
significant. All analyses were conducted using SAS version
9.4 (Cary, NC).
Results
From May 2009 to May 2013, the iMAGE study team
constituted the population-based, frequency-matched,
case–control study that includes a total of 790 participants
(277 cases and 513 controls). Of the 344 eligible cases, 167
(83.9 %) Whites and 110 (75.9 %) Blacks were enrolled
(overall case participation rate, 80.5 %). Reasons for
refusal to participate include, refused to be interviewed
(2.5 % Whites, 8.3 % Blacks), patient too ill (2.0 %
Whites, 0.7 % Blacks), or other (11.6 % Whites, 15.2 %
Blacks). Cases with extramedullary or solitary plasmacy-
toma (without evidence of end organ damage, clonal bone
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marrow plasma cells C60 %, FLC ratio[100 or focal bone
lesion [5 mm by MRI), amyloidosis, Waldenstro¨m
Macroglobulinemia, monoclonal immunoglobulin deposi-
tion disease, Polyneuropathy Organomegaly Endocrinopa-
thy Edema M-protein Syndrome, (POEMS), MGUS and
HIV-1 seropositivity were excluded (n = 17). An addi-
tional case withdrew participation and was terminated from
the study. After initial eligibility screening, participation
rates for controls were 80.8 % (79.7 % for Whites and
82.3 % for Blacks). Enrolled controls later discovered to
have MGUS (n = 1), be duplicates (n = 2), related to a
case (n = 4), reported a shared residential area with a case
or other enrolled control for 2 or more years (n = 32) and
with reported diagnoses of cancer, myelodysplastic syn-
drome (n = 7), HIV-1 infection (n = 4) or solid organ
transplant (n = 2) were excluded leaving a total of 259
cases and 461 controls available for analysis.
Distributions of demographic characteristics of partici-
pants enrolled in the iMAGE study of myeloma are shown
in Table 1. In the combined population, cases and controls
did not differ substantially by race; however, modest non-
clinically significant differences were observed by age and
sex despite frequency matching on these factors, of which,
the latter is indicative of a disproportionately higher par-
ticipation rate among female controls. Of the total 259
cases, the majority were male (54.8 %) with a mean age of
60 years at the time of diagnosis. Black cases were sig-
nificantly younger at diagnosis compared to White cases
(mean age, 58 vs. 61 years; p = 0.005) and Black cases
reported less education (p = 0.006), annual household
income (p = 0.004) and fewer relatives affected with any
cancer (p = 0.0002) than their White counterparts.
The estimated risk of MM associated with a family
history of cancer is shown in Table 2. In the combined
population, the majority of participants reported a family
history of cancer (79.9 %), including any solid tumor
(74.3 %) and any of the combined four hematologic
malignancies (NHL, HL, leukemia and MM; 16.4 %).
Among controls with any relative affected with any
hematologic malignancy, family history of leukemia was
the most prevalent (n = 32; 7 %) followed by NHL
(n = 20; 4 %), MM (n = 11; 2 %) and HL (n = 6; 1 %),
consistent with the prevalence of these hematologic
malignancies in the general US population.
In cases with any relative affected with any hematologic
malignancy, the risk of MM was significantly elevated
compared to controls (OR 1.89, 95% CI 1.25–2.86). The
magnitude of this effect was greater in Blacks (OR 2.43,
95% CI 1.13–5.22) than in Whites (OR 1.77, 95% CI
1.08–2.91), although the difference in the magnitude of
effect by race was not statistically significant (p = 0.532).
The risk of MM associated with a family history of MM
was higher than the risk associated with any hematologic
malignancy (OR 3.75, 95% CI 1.75–8.05), and this effect
was greater for Blacks (OR 20.9, 95% CI 2.59–168) than
Whites (OR 2.04, 95% 0.83–5.04). Although risk estimates
are based in a small sample, these relationships were
substantiated in an analysis restricted to participants who
reported MM among first-degree relatives only (Blacks:
OR 10.8, 95% CI 1.22–94.8; Whites: OR 1.19, 95% CI
0.28–5.16; data not shown). In contrast, increased risk of
MM among cases with a family history of NHL, HL or
leukemia (hematologic malignancy excluding MM) was
present in Whites (OR 1.71, 95% CI 1.01–2.89), whereas
no association was observed in Blacks.
Sample size precluded our ability to evaluate MM risk
by race further stratified by sex or age. In the combined
population, risks associated with a family history of MM
were elevated among cases with two or more affected
relatives with any cancer, any hematologic malignancy or
MM (p trend C0.001) (Supplementary Table 1). In addi-
tion, the influence of a positive family history of myeloma
had a greater magnitude of effect in patients with early age
of onset (B60 years of age; OR 4.58, 95% CI 1.21–17.3),
although the difference by age strata was not statistically
significant, and risk estimates were similarly elevated in
males and females (Table 3).
The estimated risk of MM associated with a family
history of solid tumors is shown in Table 2. In the com-
bined population, the risk of MM was modestly elevated
with a family history of any solid tumor (OR 1.55, 95% CI
1.06–2.27) and for the combined category of gynecologic
cancers (OR 1.95, 95% CI 1.11–3.43). Affected relatives
with a history of head and neck cancer were strongly
associated with MM risk only in Blacks (OR 6.98, 95% CI
1.85–26.4), whereas the excess risk among those with a
family history of genitourinary cancers (excluding pros-
tate) was present only in Whites (OR 2.69, 95% CI
1.12–6.46), albeit findings may be limited by sample size.
Although the risk of MM was modestly elevated with a
family history of a variety of solid tumors, no single solid
tumor type included in any of the combined solid tumor
categories achieved a level of statistical significance.
Differences in the distribution of clinical features of
MM cases with and without a family history of any
hematologic malignancy are shown in Table 4. Of the 57
MM cases with a family history of hematologic malig-
nancy, kappa (j) light chain restriction was detected in 43
(78.2 %) MM cases compared to 115 (64.3 %) MM cases
without a family history of hematologic malignancy
(p = 0.045). No notable difference in MM risk was
observed for light chain MM (p = 0.616). However, in
cases with heavy-chain MM, individuals with a family
history of hematologic malignancies were more likely to
exhibit IgG kappa MM, with a notable j light chain
restriction (OR 3.23, 95% CI 1.13–9.26; p = 0.029) after
84 Cancer Causes Control (2016) 27:81–91
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the heavy-chain isotype (IgG, IgA) was held constant. Of
the diagnostic criteria for end organ damage, the presence
of anemia and renal insufficiency, attributed to MM, was
notably less frequent consistent with a twofold reduction in
risk of MM in cases with a family history of hematologic
malignancy compared to those without, whereas hyper-
calcemia and lytic bone lesions were more frequent, albeit
not significantly (p C 0.230). We found no other
notable differences in the distributions of clinical charac-
teristics among MM cases with and without a family his-
tory of hematologic malignancies. Insufficient sample size
precluded our ability to evaluate MM-defining clinical
features stratified by race.
Discussion
MM is significantly more common in Blacks. However, our
current understanding of MM is largely based on studies
from patients of European origin. Thus, epidemiologic
studies that include well-characterized MM patients from
racially diverse populations are warranted to significantly
improve our understanding of MM etiology and to provide
a rationale for the differences observed in Black and White
MM patients. To our knowledge, this is the first report of a
comprehensive evaluation of the contribution of family
history of hematologic malignancies and other cancers on
the risk of MM, which included differences in Blacks and
Whites and among cases, the presence of MM-defining
clinical features. We observed a 3.75-fold increased overall
risk of MM among participants who reported a family
history of MM, and the effect was notably greater, by an
order of magnitude, in Blacks than Whites (ORs 21 and 2,
respectively), albeit our sample was small. In an evaluation
of clinical features in MM cases with and without a family
history of hematologic malignancy, anemia and renal
insufficiency, attributed to MM, were less common,
whereas hypercalcemia and lytic bone lesions were more
common, albeit not significantly. In addition, we found a
significant proportion of j light chain restricted disease
Table 1 Characteristics of participants enrolled in the Molecular And Genetic Epidemiology (iMAGE) study of myeloma, overall and stratified
by race
Demographic characteristics White Black
Case Control Case Control
No. of persons (%) 154 (59.4) 263 (57.1) 105 (40.5) 198 (43.0)
Mean age, years (SD)a 61.3 (8.2) 64.9 (10.2) 58.0 (10.4) 59.2 (11.9)
Sex, n (%)a
Male 99 (64.3) 142 (54.0) 43 (41.0) 67 (33.8)
Female 55 (35.7) 121 (46.0) 62 (59.1) 131 (66.2)
Education, n (%)
High school graduate or less 34 (22.4) 41 (15.6) 40 (38.1) 49 (24.7)
Some college, college graduate or post-graduate education 118 (77.6) 222 (84.4) 65 (61.9) 149 (75.3)
Smoking status, n (%)b
Never smoker 85 (55.2) 121 (46.0) 57 (54.3) 98 (50.0)
Ever smoker 69 (44.8) 142 (54.0) 48 (45.7) 98 (50.0)
Alcohol consumption, n (%)c
Never drinker 79 (51.3) 126 (47.9) 62 (59.0) 112 (56.6)
Ever drinker 75 (48.7) 137 (52.1) 43 (41.0) 86 (43.4)
Annual household income at enrollment, n (%)
Less than 20,000 14 (14.1) 24 (11.5) 20 (28.2) 50 (35.7)
20,000–29,999 10 (10.1) 26 (12.4) 13 (18.3) 29 (20.7)
30,000–49,999 23 (23.2) 40 (19.1) 19 (26.8) 36 (25.7)
50,000–99,999 27 (27.3) 70 (33.5) 13 (18.3) 19 (13.6)
100,000 or more 25 (25.3) 49 (23.4) 6 (8.5) 6 (4.3)
No. relatives with cancer, mean (SD) 2.8 (2.4) 2.0 (1.7) 1.8 (1.5) 1.5 (1.7)
a Among European Americans, controls were significantly older than cases (65 vs. 61 years, respectively; p = 0.002), albeit this difference is
not clinically significant and falls within the expected range of values based on frequency matching ±5 years. In addition, in the total population,
the proportion of male controls to cases was modestly lower than in females (p = 0.04). No other comparison in the total population reached a
level of statistical significance, p[ 0.05
b Smoking status (ever smoker) defined as having smoked more than 100 cigarettes in a lifetime
c Alcohol consumption (ever drinker) defined as at least one alcoholic beverage (beer, wine, hard liquor) per week for 6 months or longer
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among MM patients with familial coaggregation of any
hematologic malignancy.
The overall elevated risk of MM observed in our study
is consistent with previous findings from case–control
studies of patients with first-degree relatives with MM,
yielding risk estimates ranging from twofold to sixfold [16,
17]. Our risk estimates are also similar to estimates gen-
erated from large, registry-based studies, where family
history data were verified, thereby providing support for
the validity and generalizability of our findings despite the
possibility of bias in recalling cancer diagnoses in family
members, which may differ by case–control status [25]. In
the largest study published to date, which included 37,838
first-degree relatives of 13,896 patients with MM diag-
nosed in Sweden between 1958 and 2005, the risk of MM
was increased 2.1-fold in first-degree relatives with MM
(95% CI 1.6–2.9) [19], and in the Swedish registry study
preceding this, the risk of MM was increased 4.25-fold
(95% CI 1.81–8.41) [18]. In addition, Camp et al. [26]
confirm this association in 177,226 first-, second-, and
third-degree relatives linked to 1,354 MM patients inclu-
ded in the Utah Surveillance, Epidemiology and End
Results (SEER) cancer registry. Findings originating from
these large, population-based, registry studies yield precise
estimates of association by virtue of providing sufficient
statistical power; however, interpretations from registry-
based studies thus far have been limited to persons of
European origin.
Evidence for a stronger familial association of MM in
Blacks observed in our study coincides with findings from
the only population-based case–control study published to
date, in which Brown et al. [20], report an elevated risk of
MM in patients with affected first-degree relatives with
MM of 17.4-fold (95% CI 2.4–348) in Blacks and 1.5-fold
(95% CI 0.3–6.4) in Whites. Thus, despite the relatively
small number of affected relatives with MM, strength and
consistency of findings from this study and ours suggests a
familial predisposition to MM, which is greater for Blacks
than Whites. Together, these observations suggest that the
excess familial risk of MM contributes, at least in part, to
the overall increased incidence of MM observed in Blacks.
However, because the frequency of familial MM in the
general US population is low in both racial populations,
germline susceptibility appears to contribute to only a
proportion of the overall risk, emphasizing that both
genetic and environmental factors play an etiologic role in
this common complex disease.
Our observation that coaggregation of hematologic
malignancies (i.e., NHL, HL, leukemia) in families of
patients with MM occurs only in Whites, could suggest a
common etiology of select lymphomas and leukemias in
persons of European origin and conversely, specificity for
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Table 4 Clinical features and laboratory characteristics of multiple myeloma cases with and without a family history of any hematologic
malignancy
Clinical feature and laboratory
characteristica
MM case with affected
relative (n = 57)
MM case with unaffected
relative (n = 200)
OR (95% CI)b p
Clonal bone marrow plasma cells
(BMPC), median (range) %
40 (3–97) 50 (1–100) – 0.490
Serum monoclonal protein, median
(range) g(dL)
2.6 (0.1–9.5) 2.6 (0.1–10.5) – 0.442
Abnormal free light chain (FLC) ratio
(\0.26 or[1.65), n (%)
28 (90.3) 101 (92.3) 0.68 (0.16–2.85) 0.597
Light chain disease, n (%) 12 (21.4) 42 (23.5) 0.83 (0.39–1.74) 0.616
Immunoglobulin (Ig)-G isotype, n (%)c 33 (75.0) 99 (74.4) 1.03 (0.46–2.78) 0.946
Kappa free light chain, n (%)d 43 (78.2) 115 (64.3) 2.08 (1.02–4.25) 0.045
b2-Microglobulin, median (range) mg/dL 3.3 (1.4–21.6) 3.9 (0.6–32.1) – 0.701
Creatinine, median (range) mg/dL 1.1 (0.6–11.9) 1.2 (0.5–26.2) – 0.236
Albumin, median (range) mg/dL 3.5 (1.6–4.9) 3.5 (1.6–4.8) – 0.220
End organ damage, n (%)
Hypercalcemia (serum calcium
[11.5 mg/dL)
11 (23.4) 25 (16.0) 1.66 (0.73–3.77) 0.230
Renal insufficiency (serum creatinine
[2 mg/dL)
7 (14.6) 41 (26.3) 0.48 (0.20–1.81) 0.111
Anemia (hemoglobin\10 or[2 g/dL
below the lower limit of normal)
24 (48.0) 110 (69.6) 0.43 (0.22–0.83) 0.011
Bone lesions (lytic lesions, pathologic
fractures or severe osteopenia)
43 (81.1) 127 (77.0) 1.32 (0.59–2.94) 0.495
Cumulative presence of end organ damage, n (%)
1 26 (50.0) 72 (43.6) 1.0 (reference)
2 21 (40.4) 62 (37.6) 1.01 (0.51–1.99) 0.977
3 3 (5.8) 17 (10.3) 0.52 (0.14–1.96) 0.336
4 2 (3.9) 14 (8.5) 0.39 (0.08–1.90) 0.244
ISS stage, n (%)
Stage 1 12 (37.5) 43 (31.4) 1.0 (reference)
Stage 2 11 (34.4) 51 (37.2) 0.75 (0.30–1.89) 0.543
Stage 3 9 (28.1) 43 (31.4) 0.78 (0.29–2.04) 0.606
Combined immunoglobulin isotype and light chaine
IgG kappa 27 (64.3) 61 (46.6) 2.12 (1.02–4.42) 0.043
IgG lambda 5 (11.9) 36 (27.5) 0.35 (0.12–0.96) 0.042
IgA kappa 6 (14.3) 18 (13.7) 1.04 (0.38–2.88) 0.938
IgA lambda 4 (9.5) 16 (12.2) 0.75 (0.23–2.40) 0.623
Combined immunoglobulin isotype and light chaine
IgG lambda 5 (15.6) 36 (37.1) 1.0 (reference)
IgG kappa 27 (84.4) 61 (62.9) 3.23 (1.13–9.26) 0.029
Combined immunoglobulin isotype and light chaine
IgA kappa 6 (18.2) 18 (22.8) 1.0 (reference)
IgG kappa 27 (81.8) 61 (77.2) 1.35 (0.47–3.90) 0.580
a Laboratory characteristics were determined from serum
b Adjusted for sex, age, level of education ([high school graduate or equivalent) and race (White, Black)
c Cases with biclonal MM (n = 2), nonsecretory MM (n = 2), IgD MM (n = 1) were excluded from analysis. Cases with IgA MM served as the
referent
d Cases with nonsecretory MM (n = 2) were excluded from analysis. Cases with lambda (L) MM served as the referent
e Cases evaluated included those with heavy-chain MM. Cases with light chain MM (n = 54) were excluded from analyses
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evidence demonstrate a familial coaggregation of select
hematologic malignancies and solid tumors in blood rela-
tives of patients with MM [16, 17, 19, 26–28], suggesting a
shared etiology. However, these studies have largely been
restricted to populations of European origin. Positive evi-
dence for a shared etiology with lymphoma and leukemia
subtypes in Blacks has not been observed [20], perhaps
due, in part, to the disproportionately lower incidence
observed in this population.
In our analysis of solid tumors in blood relatives of
patients with MM, we provide evidence for familial
coaggregation of any solid tumor with MM in the com-
bined population, consistent with prior reports [16, 19, 26].
In addition, we found modest non-significant evidence for a
shared etiology with select tumor types previously shown
to co-occur in families of MM (i.e., prostate, malignant
melanoma, genitourinary cancers) [26], with the co-oc-
currence of malignant melanoma and genitourinary cancers
observed only in Whites. Our observation of familial
aggregation of head and neck cancers in relatives of MM
patients among Blacks has not been previously reported.
Additional studies are required to confirm this preliminary
finding and to investigate a biological basis for a possible
shared etiology.
Additional support for an inherited germline suscepti-
bility arises from several gnostic and agnostic gene asso-
ciation and sequencing studies, which have been used to
significantly expand the repertoire of confirmed MM sus-
ceptibility loci [29–31]. Despite recent advances in gene
discovery, it is unknown how these MM loci influence the
increased risk observed in Blacks because prior analyses
have been conducted exclusively in populations of Euro-
pean origin. Further evidence for a germline susceptibility
points to the Major Histocompatibility Complex (MHC) as
a genomic region with sufficient allelic variation by race to
account for the higher incidence of MM observed in Blacks
[32]; however, findings from genome-wide association
studies have not confirmed these relationships.
To our knowledge, this the first comprehensive case–
control study used to evaluate the contribution of family
history of any hematologic malignancy on the presence of
defining clinical features and laboratory characteristics in
MM patients. We hypothesized that MM patients with a
stronger familial predisposition are more likely to present
with clinical features and laboratory characteristics con-
sistent with increased disease burden. Although we note a
significantly younger age of MM onset and a modest non-
significant increase in the presence of lytic bone lesions in
MM patients with a familial coaggregation of hematologic
malignancies, we did not observe differences in laboratory
characteristics that are typically associated with disease
burden including M-protein, abnormal FLC ratio, percent
clonal bone marrow plasma cells, and b2-microglobulin,
nor did we observe differences by the presence of cumu-
lative organ damage or ISS staging. Lack of association
with laboratory characteristics, typically associated with
increased disease burden, may reflect inadequate statistical
power to detect modest effects. However, we did observe a
significant proportion of cases with j light chain
restriction.
One of the hallmarks of MM is the clonal proliferation
of malignant plasma cells, which produce M-protein and
cause lytic bone lesions. Because IgG is the most common
isotype and j is the most common light chain, which
constitute the M-protein, we acknowledge the possibility
that our finding could be due to chance. However, we did
not observe an over-representation of the IgG isotype in
MM patients with a familial coaggregation of hematologic
malignancies, suggesting that light chain restriction may
have a stronger familial component either by germline
susceptibility or shared environment. Findings from a
familial case series do not support a germline susceptibility
to M-protein [33]. However, j restriction in MM patients
with a familial coaggregation of hematologic malignancies
may reflect the impact of environmental exposures on a
common genetic background capable of driving an anti-
genic-dependent process. In this capacity, antigen may play
a role in selecting and expanding B cells, which eventually
promote the monoclonal expansion of plasma cells with a
predominant j light chain restriction. Evidence for an
antigenic-dependent process in the etiology of MM comes
from findings that prior exposure to select pathogens and
autoimmune disease are associated with MM risk [34–38].
Additional epidemiologic and molecular studies are war-
ranted to confirm these findings and to elucidate the role of
an antigen-dependent process in MM etiology.
This investigation was specifically designed to evaluate
risk factors associated with MM and differences in well-
characterized Black and White MM cases and matched
controls. However, interpretation of our findings is not
without limitation. Despite efforts to minimize the effect of
recall bias by adjusting for factors related to the accuracy
of self-reported family history and with the disparity in
MM incidence by race (i.e., age, sex, race, education) [25,
39], residual bias resulting from potential differences in
case–control reporting may lead to an overestimation of
risk. However, the consistency of findings with previously
published reports from population-based registry studies
suggests that any potential bias was unremarkable.
Although we do not anticipate differences in family size by
case–control status or in Blacks and Whites in our region,
we recognize the possibility that family size could influ-
ence the effect of family history of cancer on the risk of
MM because larger families provide more persons at risk
for disease. Finally, sample size and the inability to sys-
tematically obtain and validate family history data
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precluded our ability to evaluate familial coaggregation of
leukemia subtypes by race and to delineate relationships of
MM-defining clinical features, family history of MM in
first-degree relatives and differences by race or other
meaningful strata (e.g., early age of onset). Additional
large, well-characterized and racially diverse populations,
made available through multi-center cancer consortia, will
be required to further delineate these relationships.
In summary, we confirm a positive association of
familial risk of MM, which is greater in Blacks, and
describe for the first time, variation in the presence of
defining clinical features in MM patients according to
family history of hematologic malignancy. Although we
cannot exclude the possibility that our observed associa-
tions and patterns of inheritance might be due to chance,
the consistency of our results supports a combined germ-
line and environmental susceptibility. Our findings under-
score the importance of further characterizing germline and
somatic variation in addition to the mechanisms by which
previous environmental exposures modify the genetic
predisposition to disease [40–42] in similarly well-char-
acterized racially diverse populations. Such characteriza-
tions may facilitate improvements in our ability to predict
clinical progression, response to treatment and underlying
biologic mechanisms.
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